Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APECS II: PECS II Block with liposomal bupivacaine vs levobupivacaine for mastectomy
2024-515183-30-00Phase 3Authorised
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in postoperative pain, Persistent postsurgical pain (PPSP) and breast cancer comparing Exparel PECS II block with Levobupivacaine PECS II block (2 arms). Primary endpoint: Postoperative NRS pain scores in the breast. Planned start Jun 2024; status: authorised.
02
Drugs
bupivacainelevobupivacaine
03
Conditions
postoperative painPersistent postsurgical pain (PPSP)breast cancer
Beyond the preview
Go deeper on 2024-515183-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515183-30-00.